The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer

This study explores the potential of dinaciclib, a drug that inhibits certain enzymes called cyclin-dependent kinases (Cdks), as a treatment for biliary tract cancer (BTC). Cdks play a role in cell growth and are often abnormal in cancer cells. The researchers tested dinaciclib on BTC cells grown in the lab and found that it reduced cell growth, energy levels, and proliferation. It also triggered cell death by increasing the activity of certain enzymes (caspases) and reducing the levels of proteins that prevent cell death. Dinaciclib also affected the levels of proteins that regulate cell growth, such as EGFR and STAT3, suggesting that it can disrupt tumor growth pathways. Overall, the study suggests that dinaciclib could be a promising treatment for BTC and warrants further investigation.

• 1
  Dinaciclib reduces cell viability, ATP levels, and proliferation rates in BTC cells.
• 2
  Dinaciclib induces apoptosis via increased caspase 3/7 activity and reduced expression levels of the anti-apoptotic protein Mcl-1.
• 3
  Dinaciclib affects different cell growth regulators like EGFR and STAT3 on gene and protein level, thus decreasing tumor growth.